GHK-Cu (Copper Peptide) Dosage: Injection, Topical Concentrations & Dosing Guide

GHK-Cu dosage depends on the route of administration. Injectable GHK-Cu protocols commonly cite about 1–2 mg per day, while topical GHK-Cu is dosed by concentration, application frequency, and duration. The 1–2 mg injectable range is a contemporary protocol convention rather than a standardized dose established by controlled human dose-ranging trials.

Topical GHK-Cu has direct human research, including a 2026 randomized study that tested 2% GHK-Cu twice daily for 12 weeks for eyebrow hypotrichosis.¹

The relevant GHK-Cu dose depends on the route, formulation, amount or concentration, frequency, duration, intended goal, and quality of the supporting evidence.

For a broader overview of the peptide itself, see what GHK-Cu is and how it works.

GHK-Cu Dosage Chart

There is no single GHK-Cu dose that applies to injections, serums, creams, scalp products, and oral products.

 

The biggest source of confusion is the injectable figure. 1–2 mg/day is a commonly cited protocol range, not a standardized dose established through controlled human subcutaneous dose-ranging trials.

Why Do GHK-Cu Dosage Recommendations Differ?

GHK-Cu dosage recommendations can look inconsistent because they may refer to different routes, formulations, treatment goals, frequencies, durations, and types of evidence. A topical concentration cannot be compared directly with an injectable amount measured in milligrams.

The source of the dosage also matters. A physician or clinic protocol describes a current practice pattern, while a human clinical study shows what researchers actually tested. Preclinical doses from animal or cell research should not be converted directly into human regimens.

Before comparing two GHK-Cu dosage recommendations, check the route, unit, frequency, duration, intended goal, and source of evidence.

How Much GHK-Cu Is Commonly Used?

The amount depends first on route. Injectable protocols are usually expressed in milligrams per administration, while topical use is expressed through concentration, amount applied, frequency, and duration.

One contemporary physician-directed protocol uses 1 mg once daily for days 1–15, followed by 2 mg once daily for days 16–30 and then a 30-day break.² Other protocols use a steady daily amount or intermittent administration.

These examples describe how GHK-Cu is currently used or discussed in some supervised peptide settings. They do not establish an optimal dose for every person.

Topical GHK-Cu is different. Its effective exposure depends on:

• Concentration
• Amount applied
• Frequency
• Duration
• Formulation

A 2% serum and a 2 mg injection are therefore not comparable doses.

COMMON PROTOCOL means an amount or schedule currently reported by practitioners or dosing protocols.

HUMAN STUDY means researchers actually tested the concentration or regimen in people.

NOT ESTABLISHED means the available evidence does not support a standardized clinical dosage.

GHK-Cu Injection Dosage

GHK-Cu Injection Dosage Per Day

GHK-Cu injection dosage is commonly discussed at approximately 1–2 mg per day in contemporary peptide protocols.

Current protocols are not identical. Some use approximately 1 mg daily, others use 1–2 mg daily, and some increase from 1 mg to 2 mg during a defined cycle.²

 

These numbers answer the question, “What GHK-Cu injection doses are currently being used or discussed?”

They do not answer the separate question, “What dose has controlled human research established as optimal?”

Is 1–2 mg of GHK-Cu Clinically Established?

No controlled human dose-ranging study establishing 1–2 mg/day as the optimal subcutaneous GHK-Cu dosage was identified in the evidence reviewed for this guide.

This distinction matters because the human GHK-Cu literature is weighted much more heavily toward topical and preclinical research. A 2026 critical review characterized the human clinical record as limited and emphasized substantial gaps in formulation characterization and clinical translation.³

1–2 mg/day = commonly cited injectable protocol.

1–2 mg/day does not equal a proven optimal human dose.

FDA also states that compounded injectable GHK-Cu may pose immunogenicity risks related to aggregation and peptide-related impurities and that human safety data are limited.⁴

GHK-Cu Dosage Per Day vs. Weekly Dosage

There is no established weekly GHK-Cu dose. Current injectable protocols are generally described by the amount per administration and frequency, such as daily or intermittent use, rather than by one validated milligram-per-week target.

Some protocols use approximately 1 mg daily. Others use a 1–2 mg daily range, escalation schedules, or intermittent administration.

There is not enough controlled human evidence to show that one of these schedules is superior.

It is also misleading to create an “evidence-based weekly dose” simply by multiplying a daily protocol by seven. Frequency is part of the regimen itself, and a mathematical weekly total is not automatically a clinically studied weekly dosage.

GHK-Cu Dosage Schedule and Cycle

A dose tells you how much GHK-Cu is being discussed. A schedule tells you how often. A cycle tells you how long the protocol continues and whether it includes a break.

What Is a Common GHK-Cu Dosage Schedule?

One current physician-directed schedule is:

• Days 1–15: 1 mg once daily
• Days 16–30: 2 mg once daily
• After day 30: 30-day break

This is an example of a contemporary clinic protocol rather than a standardized medical dosing schedule.²

Other protocols use steady daily or intermittent administration rather than escalation.

How Long Is a GHK-Cu Cycle?

Current injectable protocols commonly describe defined treatment periods rather than indefinite administration.

Examples include approximately 30-day active cycles and treatment periods lasting several weeks. Rest periods also vary.

These are protocol conventions rather than cycle lengths established by comparative human trials.

Does GHK-Cu Need to Be Cycled?

There is no well-established controlled human evidence showing that GHK-Cu must follow one specific on-and-off cycle.

A clinic may use a 30-day treatment period followed by a break. That tells us how the clinic structures its protocol; it does not prove that a 30-day rest is biologically necessary or superior to every alternative.

Study duration and cycle length also are not synonymous. A topical study lasting 12 weeks demonstrates what researchers studied, not that every topical GHK-Cu product must be “cycled” for 12 weeks.

What Is the Best GHK-Cu Dosage?

There is no single best GHK-Cu dosage across all routes and goals.

If you are comparing current injectable protocols, 1–2 mg/day is a commonly cited range. If you are evaluating topical GHK-Cu, the more useful questions are what concentration was used, how often it was applied, how long it was used, and whether that formulation was actually evaluated in humans.

This route-specific distinction explains many apparent contradictions between GHK-Cu dosage guides.

• An injectable protocol may discuss milligrams per day.
• A cosmetic study may discuss a topical formulation applied twice daily.
• A hair study may specify a 2% serum.
• A wound study may use a metered topical clinical formulation.

All involve GHK-Cu, but they do not establish interchangeable doses.

GHK-Cu Topical Dosage and Concentration

Topical GHK-Cu is primarily interpreted through concentration, application amount, frequency, duration, and formulation.

What GHK-Cu Concentrations Have Been Studied?

There is no single topical percentage established as optimal for facial skin.

Older human cosmetic studies evaluated GHK-Cu-containing facial and eye formulations, including treatment periods of approximately 12 weeks. However, the available literature does not characterize these older formulations well enough to turn them into a universal percentage recommendation.³

The clearest recent concentration comes from hair-related topical research.

In 2026, researchers evaluated 2% GHK-Cu serum applied twice daily for 12 weeks for eyebrow hypotrichosis.¹

That gives us a clearly studied concentration for that specific application. It does not establish 2% as the best concentration for facial anti-aging, the eye area, scalp hair, or wound care.

What Do 2%, 4%, and 10% GHK-Cu Mean?

Commercial topical products may contain different declared concentrations, but a higher percentage should not automatically be interpreted as a better dose.

For example, 2% has been tested in a recent human eyebrow study.

That does not establish:

• 2% as the ideal eye-area anti-aging concentration
• 4% as the ideal concentration for the face or neck
• 10% as the most effective concentration because it is numerically higher

Those conclusions would require evidence that directly compares concentrations for the same application.

Does a Higher GHK-Cu Percentage Work Better?

Not necessarily. There is no established concentration-response rule showing that higher-percentage topical GHK-Cu products consistently produce better clinical results.

Formulation matters. The copper-binding state, stability, vehicle, skin penetration, local exposure, and other formulation characteristics can affect what a percentage means biologically.³

A product's percentage should therefore not be treated as a standalone measure of effectiveness.

How Often Is Topical GHK-Cu Used?

Topical frequency depends on the formulation and its directions.

Human studies provide some useful reference points. Several historical cosmetic studies evaluated GHK-Cu-containing formulations over approximately 12 weeks, while the recent eyebrow trial used twice-daily application for 12 weeks.¹

This establishes that twice-daily use has been studied in certain formulations. It does not establish twice daily as a mandatory frequency for every GHK-Cu product.

GHK-Cu Dosage for Skin and Anti-Aging

Topical application has a more direct human evidence base than the injectable anti-aging protocols commonly discussed online.

Historical studies summarized in scientific reviews include facial and eye-area GHK-Cu formulations used over approximately 12 weeks. These reports have described changes in measures associated with photoaged skin, but limitations in formulation characterization make it difficult to extract one universal percentage and call it the optimal anti-aging dose.³

For skin and anti-aging, human research supports the study of topical GHK-Cu formulations, but it has not established a single optimal commercial percentage.

If you use a specific GHK-Cu serum, cream, or lotion, follow that product's labeled application amount and frequency rather than attempting to convert an injectable milligram dose into a topical amount.

GHK-Cu Dosage for Hair Growth

There is no standardized GHK-Cu concentration or injectable dose established specifically for scalp hair growth.

The clearest recent human dosage data come from eyebrow research.

What GHK-Cu Dosage Has Been Studied for Hair?

A 2026 randomized, double-blind, vehicle-controlled split-face trial included 18 healthy adults aged 18–40 with eyebrow hypotrichosis.

Participants used:

• 2% GHK-Cu serum
• Twice daily
• For 12 weeks

on one eyebrow, while vehicle was applied to the other.

The GHK-Cu-treated side showed significant improvements in eyebrow hair count and diameter, particularly at week 12. No serious adverse effects or allergic reactions were reported.¹

Evidence status: HUMAN STUDY

This is one of the clearest GHK-Cu dosage examples because concentration, frequency, duration, population, and outcome were all specified.

However, the study examined eyebrow hypotrichosis. It does not establish 2% as the optimal dose for male pattern hair loss, female pattern hair loss, or other scalp conditions.

GHK-Cu Injection Dosage for Hair Growth

No hair-specific injectable GHK-Cu dosage has been established by controlled human research.

The 1–2 mg/day range discussed earlier comes from general injectable protocols. It should not be relabeled as a proven hair-growth dose simply because hair support is one reason GHK-Cu may be used.

GHK-Cu With Microneedling or After Skin Procedures

There is no standardized GHK-Cu dosage established specifically for microneedling.

GHK-Cu has been evaluated after another skin procedure—CO₂ laser resurfacing—but that evidence should not automatically be transferred to microneedling.

In a randomized study, 13 patients completed a comparison of post-CO₂-laser skincare regimens with or without topical GHK-Cu. Objective evaluation found no statistically significant advantage for GHK-Cu in post-treatment erythema, wrinkles, or overall skin quality, although patient-reported satisfaction was higher with GHK-Cu.⁵

Evidence from post-laser treatment therefore does not establish an optimal GHK-Cu concentration, amount, or timing for microneedling.

Does GHK-Cu Dosage Change With Age?

No validated GHK-Cu dosage has been established specifically for adults over 40, 45, 50, or 60.

Older adults have been represented in topical GHK-Cu research, but participation by a particular age group does not establish a separate age-specific dose.

Skin sensitivity, health conditions, medications, and the intended treatment goal may still differ between individuals. Those factors may affect clinical decisions, but they do not justify inventing a separate “50+ GHK-Cu dose” without supporting evidence.

Is There a Different GHK-Cu Dosage for Women?

No standardized female-specific GHK-Cu dose has been established.

Several historical cosmetic studies enrolled women, but that does not demonstrate that women require a distinct topical concentration or injectable dose.

For topical use, formulation and tolerance are more relevant than creating a dosage based solely on sex.

Pregnant or nursing users should follow the warnings on the individual product and discuss supplement or medical use with an appropriate healthcare professional.

Oral and Sublingual GHK-Cu Dosage

A standardized human oral or sublingual GHK-Cu dosage was not identified in the evidence reviewed for this guide.

This is another situation where a product serving size should not be confused with an established clinical dosage.

An ingestible product may contain a defined amount of GHK-Cu per serving. That number describes the formulation and label directions; it does not establish the same amount as an optimal universal oral dose.

Our GHK-Cu tablets are an example: each tablet is labeled at 2 mg and taken sublingually, and that figure describes the product, not a clinically established oral dose.

Do not attempt to convert an injectable milligram amount or topical percentage into an oral serving. Route of administration changes how dosing information has to be interpreted.

Intranasal products follow the same rule: our GHK-Cu nasal spray is labeled per spray (625 mcg), which is a formulation figure, not a dose derived from injectable protocols.

For a deeper route-specific discussion, see can GHK-Cu be taken orally?

What GHK-Cu Dosages Have Actually Been Studied in Humans?

Human evidence is easier to interpret when it is separated from contemporary peptide protocols.

 

The diabetic-ulcer study was multicenter, randomized, evaluator-blinded, and placebo-controlled. GHK-Cu gel used alongside standardized wound care improved plantar-ulcer closure compared with vehicle.⁶

But a topical medical wound formulation does not establish a facial cosmetic dose, just as a topical eyebrow study does not establish a subcutaneous systemic dose.

A 2026 critical review reaches a similar broader conclusion: GHK-Cu has extensive biological and preclinical interest, but its human clinical evidence remains limited and formulation characterization is frequently inadequate.³

GHK-Cu Reconstitution and Dosage Calculations

GHK-Cu reconstitution can create dosing confusion because milligrams, milliliters, concentration, and syringe units describe different things.

• mg (milligrams): amount of GHK-Cu
• mL (milliliters): liquid volume
• mg/mL: concentration of GHK-Cu in that liquid
• Syringe units: volume markings determined by the syringe being used

These values cannot be substituted for one another without the missing concentration and volume information.

How Is GHK-Cu Concentration Calculated?

The basic concentration equation is:

Concentration (mg/mL) = total GHK-Cu (mg) ÷ final solution volume (mL)

For example, a hypothetical solution containing 50 mg of GHK-Cu in a final volume of 10 mL has a concentration of:

50 mg ÷ 10 mL = 5 mg/mL

This calculation describes the solution's concentration. It does not determine what dose someone should use.

The dosage decision and the concentration calculation are separate questions.

Why Reconstitution Changes Concentration, Not Total Peptide Amount

Changing the liquid volume changes the concentration, not the original amount of GHK-Cu.

If the same 50 mg were distributed through a larger final volume, each milliliter would contain less GHK-Cu. If it were distributed through a smaller volume, each milliliter would contain more.

The total amount remains 50 mg.

This is also why statements such as “I use X syringe units” are incomplete as dosage information. A volume marking cannot tell you the number of milligrams without knowing the concentration and syringe calibration.

This guide does not provide instructions for preparing or self-injecting GHK-Cu. Injectable dosing and preparation require appropriate medical and pharmacy oversight.

GHK-Cu Dosage and Side Effects

Human studies have not established a clear dose-response curve showing how GHK-Cu side-effect risk changes at specific injectable doses or topical concentrations. A larger injectable amount or higher topical concentration should therefore not automatically be considered safe simply because it appears in a commercial product or contemporary protocol.

Safety also differs by route, so topical tolerability data cannot establish the safety of an injectable dose.

Topical GHK-Cu

Topical products can cause irritation or sensitivity in some users, depending on the formulation and individual skin.

Possible reactions can include redness, itching, dryness, stinging, or other irritation.

In the 2026 eyebrow study, no serious adverse effects or allergic reactions were reported during 12 weeks of twice-daily 2% GHK-Cu use, but the study included only 18 participants.¹

A small trial cannot establish the maximum safe concentration for every population or formulation.

Injectable GHK-Cu

Injectable use introduces additional concerns, including dosing errors, injection-site complications, contamination, formulation quality, and immunogenicity.

FDA states that compounded injectable GHK-Cu may pose an immunogenicity risk because of possible aggregation and peptide-related impurities and that human safety data are limited.⁴

As of FDA's May 14, 2026 update, GHK-Cu except for injectable routes was returned to Category 1 of the agency's Section 503A bulk-substance evaluation process after clarification that only the injectable-route nomination had been withdrawn.⁷

That regulatory process does not establish an injectable dose.

Is There a Maximum Safe GHK-Cu Dose?

A maximum safe injectable GHK-Cu dose has not been established by robust human dose-ranging evidence.

A high end appearing in a practitioner protocol is not the same thing as a clinically demonstrated safety ceiling.

The same caution applies to dietary copper limits. A dietary copper intake limit should not be converted into a supposed injectable GHK-Cu limit because those are different forms and routes of exposure.

For broader safety information, see GHK-Cu side effects.

Common GHK-Cu Dosing Mistakes

1. Treating a Common Protocol as a Proven Dose

1–2 mg/day is useful for describing current injectable protocol practice. It should not be relabeled as a proven optimal or maximum-safe dose.

2. Confusing mg With mL

Milligrams measure GHK-Cu amount. Milliliters measure liquid volume. You need the solution concentration to relate one to the other.

3. Treating Syringe Units as Milligrams

Syringe units are volume markings. They do not independently tell you the amount of GHK-Cu.

4. Assuming a Higher Topical Percentage Is Better

The available human evidence does not establish a universal concentration-response ladder where 10% must work better than 4%, or 4% better than 2%.

5. Turning the 2% Eyebrow Study Into a Scalp Dose

Researchers tested 2% twice daily for 12 weeks for eyebrow hypotrichosis.¹ That does not establish the same concentration as optimal for scalp pattern hair loss.

6. Treating Study Duration as a Required Cycle

A 12-week study means researchers evaluated that regimen for 12 weeks. It does not prove everyone needs a 12-week GHK-Cu cycle.

7. Converting Animal Research Into Human Dosage

A large portion of the GHK-Cu evidence base is preclinical.³ Amounts used in cell cultures or animal models should not be converted directly into human dosing recommendations.

8. Mixing Evidence From Different Routes

A topical wound dose does not establish a facial-serum concentration. A topical eyebrow concentration does not establish a subcutaneous dose. An injectable clinic protocol does not establish an oral serving.

Route is part of the dosage.

GHK-Cu Dosage FAQ

How much GHK-Cu is commonly used per day?

Approximately 1–2 mg per day is commonly cited for subcutaneous GHK-Cu in current peptide protocols. Some physician-directed protocols start at 1 mg daily before increasing to 2 mg daily. These are protocol conventions rather than an optimal dose established by controlled human subcutaneous trials.

What is the typical subcutaneous GHK-Cu dosage?

A common current range is 1–2 mg subcutaneously per day. Other schedules also circulate, including intermittent administration, so there is no single standardized injection regimen.

How often is GHK-Cu used?

Current injectable protocols frequently use daily administration, although intermittent schedules exist. Topical frequency depends on the formulation; twice-daily application has been evaluated in human research, including the 2026 2% eyebrow study.

How long is a GHK-Cu cycle?

Some current injection protocols use 30 days of treatment followed by a break, while others describe treatment periods lasting several weeks. No single optimal cycle length has been established by controlled human research.

What concentration of GHK-Cu is used topically?

There is no universally established optimal topical percentage. 2% GHK-Cu serum applied twice daily for 12 weeks has been tested in a randomized eyebrow study, but this does not establish 2% as the best concentration for every topical use.

What GHK-Cu dosage has been studied for hair growth?

The clearest recent human regimen is 2% topical GHK-Cu serum twice daily for 12 weeks in adults with eyebrow hypotrichosis. It should not automatically be generalized to scalp hair loss.

Does GHK-Cu dosage change after age 45?

No specific GHK-Cu dosage has been established for people over 45. Age-specific dosage charts should therefore not be presented as clinically established without supporting evidence.

What is the maximum safe GHK-Cu dosage?

A maximum safe injectable dose has not been established by robust human clinical evidence. FDA also notes limited human safety data for compounded injectable GHK-Cu.⁴

The Takeaway

GHK-Cu dosage depends on route.

For subcutaneous GHK-Cu, approximately 1–2 mg per day is a commonly cited contemporary protocol range. A current physician-directed example uses 1 mg daily for days 1–15 followed by 2 mg daily for days 16–30, but controlled human research has not established that regimen as the optimal injectable dose.

Topical GHK-Cu has more direct human evidence. The clearest recent numerical example is 2% GHK-Cu serum applied twice daily for 12 weeks in a randomized eyebrow study.¹

Human research has also evaluated topical GHK-Cu in skin, wound, and post-procedure contexts, but those formulations and doses should not be treated as interchangeable.

The simplest way to evaluate any GHK-Cu dosage claim is to ask:

• What route was used?
• What amount or concentration was tested?
• How often was it used?
• For how long?
• Was the number taken from a human study or from a contemporary protocol?

Those questions separate what has actually been studied from what is commonly repeated.

References

1. Bo SL, Nararatwanchai T, Supornpun N, Poomarapan K, Thaploka S. The Efficacy of 2% Copper Peptide (GHK-Cu) Serum for Eyebrow Hypotrichosis: A Randomized, Double-Blind, Vehicle-Controlled, Split-Face Comparative Study. Procedia of Multidisciplinary Research. 2026.
2. Beverly Hills Rejuvenation Center. GHK-Cu Dosage & Injection Protocol Guide: Reconstitution, Chart & Cycling (2026). Used here only to document a contemporary physician-directed protocol pattern, not to establish clinical efficacy, safety, or a standardized dose.
3. Mateescu D-M, Gavrilescu D-M, Mincioaga R-I, et al. GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Pharmaceutics. 2026;18(9):1077. doi:10.3390/pharmaceutics18091077.
4. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. See the entry for GHK-Cu for injectable routes of administration.
5. Effects of Topical Copper Tripeptide Complex on CO2 Laser-Resurfaced Skin. PubMed PMID: 16847171.
6. Mulder GD, Patt LM, Sanders L, et al. Enhanced Healing of Ulcers in Patients with Diabetes by Topical Treatment with Glycyl-L-Histidyl-L-Lysine Copper. Wound Repair Regen. 1994;2(4):259-269. PMID: 17147644. doi:10.1046/j.1524-475X.1994.20406.x.
7. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Updated May 14, 2026. See the GHK-Cu entry concerning non-injectable routes.